TITLE

Non-Adherence to Anti-Tuberculosis Treatment and Determinant Factors among Patients with Tuberculosis in Northwest Ethiopia

AUTHOR(S)
Adane, Akilew Awoke; Alene, Kefyalew Addis; Koye, Digsu Negese; Zeleke, Berihun Megabiaw
PUB. DATE
November 2013
SOURCE
PLoS ONE;Nov2013, Vol. 8 Issue 11, p1
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Background: Non-adherence to anti tuberculosis treatment is one of the crucial challenges in improving tuberculosis cure-rates and reducing further healthcare costs. The poor adherence to anti-tuberculosis treatment among patients with tuberculosis is a major problem in Ethiopia. Hence, this study assessed level of non-adherence to anti-tuberculosis therapy and associated factors among patients with tuberculosis in northwest Ethiopia. Methods: An institution based cross-sectional survey was conducted among tuberculosis patients who were following anti-tuberculosis treatment in North Gondar zone from February 20 – March 30, 2013. Data were collected by trained data collectors using a structured and pre-tested questionnaire. Data were entered to EPI INFO version 3.5.3 and analyzed using statistical package for social sciences (SPSS) version 20. Multiple logistic regressions were fitted to identify associations and to control potential confounding variables. Odds ratio (OR) with 95% confidence interval was calculated and p-values<0.05 were considered statistically significant. Results: A total of 280 tuberculosis patients were interviewed; 55.7% were males and nearly three quarters (72.5%) were urban dwellers. The overall non-adherence for the last one month and the last four days before the survey were 10% and 13.6% respectively. Non-adherence was high if the patients had forgetfulness (AOR 7.04, 95% CI 1.40–35.13), is on the continuation phase of chemotherapy (AOR: 6.95, 95% CI 1.81–26.73), had symptoms of tuberculosis during the interview (AOR: 4.29, 95% CI 1.53–12.03), and had co-infection with HIV (AOR: 4.06, 95% CI 1.70–9.70). Conclusions: Non-adherence to anti-tuberculosis treatment was high. Forgetfulness, being in the continuation phases of chemotherapy, having symptoms of tuberculosis during the interview, and co-infected with HIV were significantly associated with non-adherence to anti-tuberculosis therapy. Special attention on adherence counseling should be given to symptomatic patients, TB/HIV co-infected patients, and those in the continuation phase of the tuberculosis therapy.
ACCESSION #
92669125

 

Related Articles

  • Pharmacokinetic Factors in the Modern Drug Treatment of Tuberculosis. Graham Douglas, J.; McLeod, M-J. // Clinical Pharmacokinetics;1999, Vol. 37 Issue 2, p127 

    Tuberculosis is increasing in prevalence throughout the world, particularly in sub-Saharan Africa, Asia and Latin America. This resurgence can partly be attributed to increasing poverty, particularly in developing countries, and the human immunodeficiency virus (HIV) pandemic. However, there is...

  • Cost of treating HIV remains high; Louisiana feels the pain. Daugherty, Christi // New Orleans CityBusiness (1994 to 2008);12/14/98, Vol. 19 Issue 24, p25 

    Reports on the rise of drug therapy costs for HIV infection in Louisiana. Insurance coverage of patients with HIV; Average expenses of patients with HIV or AIDS; Reasons for the increase of HIV drug therapy costs; Effects of drug therapy to people with HIV.

  • High Yields of Hydrogen Production Induced by Meta-Substituted Dichlorophenols Biodegradation from the Green Alga Scenedesmus obliquus. Papazi, Aikaterini; Andronis, Efthimios; Ioannidis, Nikolaos E.; Chaniotakis, Nikolaos; Kotzabasis, Kiriakos // PLoS ONE;Nov2012, Vol. 7 Issue 11, Special section p1 

    Hydrogen is a highly promising energy source with important social and economic implications. The ability of green algae to produce photosynthetic hydrogen under anaerobic conditions has been known for years. However, until today the yield of production has been very low, limiting an industrial...

  • Correction: Cost Resulting from Anti-Tuberculosis Drug Shortages in the United States: A Hypothetical Cohort Study. Scott, James C.; Shah, Neha; Porco, Travis; Flood, Jennifer // PLoS ONE;9/2/2015, Vol. 10 Issue 9, p1 

    No abstract available.

  • Population Pharmacokinetics and its Role in Anti-Tuberculosis Drug Development and Optimization of Treatment. Egelund, Eric Free; Barth, Aline Bergesch; Peloquin, Charles Arthur // Current Pharmaceutical Design;9/11/2011, Vol. 17 Issue 27, p2889 

    Tuberculosis (TB) has survived for millennia due to its unique physiochemical properties and its ability to persist in a "dormant" state. Because of these unique properties, the treatment of TB involves multiple drugs for half of a year or longer. Although the incidence of TB has declined in...

  • TB DRUGS COMPARED.  // AIDS Patient Care & STDs;Jun2000, Vol. 14 Issue 6, p337 

    Summarizes results of a study comparing the use of two tuberculosis drugs against daily isoniazid to prevent tuberculosis in patients in HIV infection. Rate of tuberculosis among patients in the two-drug group and the isoniazid group; Levels of toxicity; Safety and efficacy.

  • Delamanid for multidrug-resistant pulmonary tuberculosis.  // African Journal of Respiratory Medicine;Sep2012, Vol. 8 Issue 1, p2 

    The article reports on the multicentre trial reported in the "New England Journal of Medicine" which shows the effectiveness of the antituberculous drug delamanid for treatment of multidrug-resistant pulmonary tuberculosis.

  • Alliance pledges new cheap TB drug by 2010. Richards, Tessa // BMJ: British Medical Journal (International Edition);10/21/2000, Vol. 321 Issue 7267, p981 

    Reports on an initiative to tackle tuberculosis (TB), called the Global Alliance for TB Drug Development, which was launched in fall of 2000 at the international conference on health research for development in Bangkok, Thailand. The goals of the alliance for antituberculosis drugs; The...

  • Comparison of Treatment Outcomes of New Smear-Positive Pulmonary Tuberculosis Patients by HIV and Antiretroviral Status in a TB/HIV Clinic, Malawi. Tweya, Hannock; Feldacker, Caryl; Phiri, Sam; Ben-Smith, Anne; Fenner, Lukas; Jahn, Andreas; Kalulu, Mike; Weigel, Ralf; Kamba, Chancy; Banda, Rabecca; Egger, Matthias; Keiser, Olivia // PLoS ONE;Feb2013, Vol. 8 Issue 2, p1 

    Background: Smear-positive pulmonary TB is the most infectious form of TB. Previous studies on the effect of HIV and antiretroviral therapy on TB treatment outcomes among these highly infectious patients demonstrated conflicting results, reducing understanding of important issues. Methods:...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics